Opinion: Problems with Hidden COI

There may be much more to conflicts of interest than what gets declared.

Written byPhilippe Grandjean
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

FLICKR, PROTEINBIOCHEMISTWhen a scientific article has an author or a list of authors, we usually have no reason to wonder who was responsible for the work. But despite increased focus on conflicts of interest (COI), recent events suggest that there may be more to authorship than a list of researchers’ names and their affiliations. Earlier this year, a court case revealed that four independent laboratories that contributed to a study on a proprietary chemical published in a peer-reviewed journal were not so independent after all. The authors declared no COI and did not include mention of any funding or other acknowledgments. But when the study was challenged by a competitor in court, it was discovered that the company that produced the chemical in question had designed the study, paid the first author to generate the manuscript, and covered all expenses incurred by the participating laboratories.

Knowing who funded the research behind scientific results is like having caller ID. If a call comes in and the number is withheld, you might become suspicious and ignore the call. Scientific authorship should be just as simple so that we can concentrate our attention on the sources we trust.

Most major journals now require that authors reveal financial relationships with any parties of potential interest to the research being reported. When perusing a paper, readers should quickly be able to find out who initiated the science, who paid for it or contributed to it, and who wrote the manuscript. It may be that this information is of no consequence, but hiding it suggests something deceitful is going on. Exactly for this reason, COI statements ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies